Clinical Trials Browser

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT02810457 2022-03-10

AVANA

Phase 3 Completed

731 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02250118 2017-11-06

BEVAP

Phase 1 Terminated

1 enrolled

BreastThoracic

Breast Neoplasms, Neoplasms, Pleural Effusion, Malignant

NCT00480831 2017-05-18

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Phase 2 Completed

128 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00741195 2016-10-04

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00741221 2016-10-04

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00755157 2015-10-07

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00653939 2015-02-09

FALCON

Phase 2 Completed

63 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00666692 2012-04-27

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

7 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00356122 2011-10-17

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

53 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

EGRET

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

PTST_PALBEVA

NТО-RAS

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

AVANA

BEVAP

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

FALCON

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)